摘要
目的探讨β-微管蛋白Ⅰ外显子4在宫颈癌患者中的基因突变与多西紫杉醇同步放疗疗效关系。方法采用焦磷酸测序法对16例宫颈癌患者新鲜组织标本和血标本中β-微管蛋白Ⅰ外显子4进行检测。于静脉滴注25mg/m2多西紫杉醇1小时后进行化疗。用临床妇科检查的方法评价多西紫杉醇同步放疗疗效,分析不同基因型与疗效的关系。结果 16例病人近期疗效均为完全缓解,没有复发,患者仍然生存。2病例中β-微管蛋白Ⅰ外显子4在217Leu发现纯合子和杂合子的同义突变,但与多西紫杉醇同步放疗疗效无关。结论由于病例有限,本实验中患者的基因突变与多西紫杉醇没有显示相关性,但仍需搜集更多病例进一步探讨两者之间的关系。
Objective To detect influence of β-tubulin Ⅰexon 4 mutations on docetaxel effect in patients with local advanced cervical cancer.Method Exon 4 of b-tubulinⅠwas amplified and sequenced,in blood and tissue samples,by pyrosequencing method.Docetaxel was administered intravenously（IV）at 25mg/m2 in 1 hour followed by radiotherapy.The response was evaluated based on pelvic physical examination.Results Complete response rate was 100%（16CR）.No progress disease was observed.All patients survive until now.Gene sequence alterations were found in 2/16（12.5%）patients.There was no relationship between sequence alterations and response to docetaxel.Conclusions Although no relevance was observed between these mutations and docetaxel effect in the limited numbers of patients,more subjects should be into the study to determine the relationship.
出处
《肿瘤药学》
CAS
2011年第6期489-492,共4页
Anti-Tumor Pharmacy
基金
湖南省科技厅资助课题资助项目(编号:2009SK3106)
